These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28602775)

  • 21. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emilia: use cunning to survive cancer.
    Gligorov J; Richard S; Pivot X
    Chin Clin Oncol; 2018 Feb; 7(1):5. PubMed ID: 29307196
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
    Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
    Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
    Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
    J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Data About First-line All-oral Vinorelbine and Capecitabine in HER2-negative Metastatic Breast Cancer Confirms Results of Meta-analysis.
    Altundag K
    Clin Breast Cancer; 2017 Jun; 17(3):e163. PubMed ID: 28161133
    [No Abstract]   [Full Text] [Related]  

  • 32. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.
    Alagizy HA; Shehata MA; Hashem TA; Abdelaziz KK; Swiha MM
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):22-7. PubMed ID: 25528114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab emtansine for HER2-positive breast cancer.
    Venkatesan P
    Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.